STAT+: MAHA goes corporate

STAT PlusNewsletterD.C. Diagnosis MAHA goes corporate You’re reading STAT’s D.C. Diagnosis newsletter Manage alerts for this article Save this story for later Share this article By John WilkersonOct.

1, 2026 Washington Correspondent John Wilkerson[email protected]John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07.

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Michigan Democratic Senate candidate Abdul El-Sayed announced his Building a Healthier America policy agenda to co-opt the MAHA movement. So it’s BAHA vs. MAHA now.

Send news tips and tortured acronyms to [email protected] or John_Wilkerson.07 on Signal.Advertisement MAHA Corp. MAHA dove headlong into the swamp this week. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Congress, Drug prices, health care costs, HHS, Medicare, Pharmaceuticals, Policy, RFK Jr., STAT+ Submit a correction requestReprints John Wilkerson Washington Correspondent John writes about the politics of health care, and he is the author of the twice-weekly D.C.

Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Adam's Biotech Scorecard October 1, 2026 STAT Plus: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy Adam's Biotech Scorecard October 1, 2026 STAT Plus: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await Advertisement A STAT Examination October 1, 2026 STAT Plus: Can a top Republican from a bygone political era fix pharma’s woes in Washington?

Biotech October 1, 2026 STAT Plus: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world Biotech September 30, 2026 STAT Plus: HHS announces new efforts to speed up, expand clinical trials with AI Subscriber Picks